{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-orphan-drug-trial-regulatory-interactions”
},
“headline”: “SOP for Orphan Drug Trial Regulatory Interactions”,
“description”: “This SOP defines standardized procedures for regulatory interactions during orphan drug clinical trials. It covers communication with FDA, EMA, CDSCO, WHO, and other global regulatory agencies to ensure compliance, efficiency, and transparency in rare disease drug development.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}
Published on 25/12/2025
Standard Operating Procedure for Orphan Drug Trial Regulatory Interactions
| SOP No. | CR/OPS/120/2025 |
| Supersedes | NA |
| Page No. | 1 of 61 |
| Issue Date | 26/08/2025 |
| Effective Date | 01/09/2025 |
| Review Date | 01/09/2026 |
Purpose
The purpose of this SOP is to establish standardized procedures for regulatory interactions in orphan drug clinical trials. Orphan drug trials involve unique challenges
Scope
This SOP applies to sponsors, regulatory affairs, investigators, CROs, and QA staff involved in orphan drug trials. It covers communication with agencies such as FDA, EMA, CDSCO, and WHO, including submissions, pre-submission meetings, regulatory queries, orphan drug designation processes, and inspection readiness.
Responsibilities
- Sponsor: Leads regulatory interactions and ensures timely submissions.
- Regulatory Affairs: Coordinates communication with global agencies and prepares documentation.
- Investigator: Provides clinical input for regulatory discussions.
- CRO: Supports submissions and monitors compliance.
- QA: Ensures that regulatory communications are archived and inspection-ready.
Accountability
The Sponsor’s Head of Regulatory Affairs is accountable for orphan drug regulatory interactions, with site-level accountability resting with the Principal Investigator.
Procedure
1. Regulatory Strategy Development
1.1 Define a regulatory roadmap early in the development program.
1.2 Document in Orphan Drug Regulatory Strategy Log (Annexure-1).
2. Orphan Drug Designation
2.1 Submit designation applications to FDA, EMA, or regional authorities.
2.2 Maintain Designation Application Log (Annexure-2).
3. Pre-Submission Meetings
3.1 Request meetings with regulatory agencies (FDA Type B/C, EMA Scientific Advice).
3.2 Document minutes in Meeting Log (Annexure-3).
4. Submission of Protocols and Amendments
4.1 Submit CTAs/INDs to authorities with orphan-specific justifications.
4.2 Maintain Submission Tracking Log (Annexure-4).
5. Handling Regulatory Queries
5.1 Assign subject matter experts to address queries.
5.2 Respond within required timelines (e.g., FDA 30 days).
5.3 Record in Regulatory Query Log (Annexure-5).
6. Inspection Readiness
6.1 Prepare for inspections specific to orphan drug trials.
6.2 Maintain Inspection Readiness Log (Annexure-6).
7. Archiving
7.1 Archive all regulatory communications and responses in TMF and ISF.
7.2 Retain per applicable regulatory requirements (e.g., 25 years in EU).
Abbreviations
- SOP: Standard Operating Procedure
- CTA: Clinical Trial Application
- IND: Investigational New Drug
- QA: Quality Assurance
- CRO: Contract Research Organization
- FDA: Food and Drug Administration
- EMA: European Medicines Agency
- CDSCO: Central Drugs Standard Control Organization
- WHO: World Health Organization
- TMF: Trial Master File
- ISF: Investigator Site File
Documents
- Orphan Drug Regulatory Strategy Log (Annexure-1)
- Designation Application Log (Annexure-2)
- Meeting Log (Annexure-3)
- Submission Tracking Log (Annexure-4)
- Regulatory Query Log (Annexure-5)
- Inspection Readiness Log (Annexure-6)
References
- FDA – Orphan Drug Development
- EMA – Orphan Drug Designation
- CDSCO – Orphan Drug Guidelines
- ICH GCP – Regulatory Interactions
- WHO – Rare Disease and Orphan Drug Trials
Version: 1.0
Approval Section
| Prepared By | Ravi Kumar, Regulatory Affairs Specialist |
| Checked By | Sunita Reddy, QA Officer |
| Approved By | Dr. Anil Sharma, Head Clinical Operations |
Annexures
Annexure-1: Orphan Drug Regulatory Strategy Log
| Date | Drug ID | Region | Strategy | Prepared By |
|---|---|---|---|---|
| 01/09/2025 | OD-101 | FDA/EMA | Expedited submission | Regulatory Team |
Annexure-2: Designation Application Log
| Date | Drug ID | Agency | Status | Submitted By |
|---|---|---|---|---|
| 02/09/2025 | OD-101 | FDA | Submitted | Regulatory Affairs |
Annexure-3: Meeting Log
| Date | Agency | Meeting Type | Attendees | Outcome |
|---|---|---|---|---|
| 05/09/2025 | FDA | Type B | PI, Regulatory Affairs | Positive |
Annexure-4: Submission Tracking Log
| Date | Drug ID | Submission Type | Agency | Status |
|---|---|---|---|---|
| 06/09/2025 | OD-101 | CTA | EMA | Under Review |
Annexure-5: Regulatory Query Log
| Date | Agency | Query | Response Deadline | Status |
|---|---|---|---|---|
| 08/09/2025 | FDA | Safety Data Request | 30 days | Pending |
Annexure-6: Inspection Readiness Log
| Date | Agency | Readiness Check | Reviewed By | Status |
|---|---|---|---|---|
| 10/09/2025 | EMA | Inspection Simulation | QA Officer | Completed |
Revision History
| Revision Date | Revision No. | Revision Details | Reason for Revision | Approved By |
|---|---|---|---|---|
| 26/08/2025 | 00 | Initial version | New SOP creation | Head Clinical Operations |
For more SOPs visit: Pharma SOP